Authors:

Abdolkhalegh Deezagi*, Bahar Ghorbani.

Department of molecular medicine, National Institute of Genetic Engineering and Biotechnology
Tehran-Iran

DOI: https://doi.org/10.52338/wjoncgy.2022.1011

Abstract:

Background: Vascular endothelial growth factor (VEGF) is a key factor in angiogenesis, tumor growth and metastasis. Various small molecules and several humanized monoclonal antibodies
against VEGF have been developed for inhibition of angiogenesis in different cancers. The aim of this work was to investigate the effect of combination of VEGF siRNA and Avastin on breast cancer MCF-7 cell line behavior.
Methods: The cells were treated by Avastin and/or VEGF siRNA and their combination. The cell survival and cell proliferation were assayed by cell counting, trypan blue and MTT tests. The cell migration was assayed by scratching test. VEGF expression was assayed by RT and real-time PCR and ELISA methods.
Results: The cell death and viability were decreased following treatment by Avastin (50% cell death at 100 μg/ml). Cell death with VEGF siRNA transfection was lower than Avastin, however, it was significant. This result in VEGF siRNA+Avastin (100 μg/ml) treatment was greater compared to treatment with each of these compounds alone (47%). Scratching results also showed the synergic effect of VEGF siRNA and Avastin (57% decrease). Real-time PCR results showed that Avastin at concentrations of ≥50 μg/ml led to 2.5 to 7.5-fold decrease in VEGF expression levels. Also, treatment with VEGF siRNA led to 15.5-fold decrease in VEGF expression. Finally, VEGF expression following VEGF siRNA+Avastin treatment led to a significant 47.5-fold decrease in
VEGF expression.
Conclusion: Combination of VEGF siRNA and Avastin have a more significant impact on the inhibition of cell growth and migration and it can probably be used as an effective therapeutic
approach.

Citation:

Abdolkhalegh Deezagi. Assessment of the synergic effect of Avastin and VEGF siRNA on inhibition of the cell proliferation, invasion and angiogenic factor expression of human breast cancer cells. World Journal of Medical Oncology 2022.